Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
825 α-CD38 therapy reverses α-PD1 resistance when used in a proper biologic schedule; explaining and overcoming previous failures of the combination in clinical trials
Compose a Response to This Article
Other responses
No responses have been published for this article.
